ArticleMicrobiology spectrum2023
Clinical Characteristics and Treatment Outcomes of Mycobacterium fortuitum Pulmonary Disease.
Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- A single-centre analysis of the clinical characteristics of non-tuberculous mycobacterial lung disease caused by rare species.IJTLD open · 2026Article
- Genomic profile and infection dynamics of Kashi_RDG1 (KRDG1), a novel cluster K1 mycobacteriophage infecting mycobacterial hosts.Frontiers in microbiology · 2026Article
- An alveolus lung-on-a-chip model of Mycobacterium fortuitum lung infection.Disease models & mechanisms · 2025Article
- An alveolus lung-on-a-chip model ofbioRxiv : the preprint server for biology · 2025Article
- Systemic Infection Caused by Mycobacterium fortuitum Following Aortic Valve Transplantation-Employing Combined Molecular Techniques for Accurate Species Identification.Current microbiology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the clinical characteristics and treatment outcomes of 35 patients diagnosed with Mycobacterium fortuitum-pulmonary disease (M. fortuitum-PD). Prior to treatment, all isolates were sensitive to amikacin and 73% and 90% were sensitive to imipenem and moxifloxacin, respectively. Approximately two-thirds of the patients (24 of 35) remained stable without antibiotic treatment. Of 11 patients requiring antibiotic treatment, the majority (81%, 9 of 11) achieved a microbiological cure with susceptible antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.